Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2009 1
2010 3
2011 3
2012 6
2013 3
2014 7
2015 5
2016 7
2017 12
2018 8
2019 5
2020 13
2021 13
2022 14
2023 9
2024 12
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Results by year

Filters applied: . Clear all
Page 1
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
A survey on data mining techniques used in medicine.
Birjandi SM, Khasteh SH. Birjandi SM, et al. J Diabetes Metab Disord. 2021 Aug 31;20(2):2055-2071. doi: 10.1007/s40200-021-00884-2. eCollection 2021 Dec. J Diabetes Metab Disord. 2021. PMID: 34900841 Free PMC article.
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kümmel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M. von Minckwitz G, et al. Lancet Oncol. 2014 Jun;15(7):747-56. doi: 10.1016/S1470-2045(14)70160-3. Epub 2014 Apr 30. Lancet Oncol. 2014. PMID: 24794243 Clinical Trial.
A Narrative Review of COVID-19: The New Pandemic Disease.
Shirani K, Sheikhbahaei E, Torkpour Z, Ghadiri Nejad M, Kamyab Moghadas B, Ghasemi M, Akbari Aghdam H, Ehsani A, Saber-Samandari S, Khandan A. Shirani K, et al. Iran J Med Sci. 2020 Jul;45(4):233-249. doi: 10.30476/ijms.2020.85869.1549. Iran J Med Sci. 2020. PMID: 32801413 Free PMC article. Review.
Can Berberine Serve as a New Therapy for Parkinson's Disease?
Dadgostar E, Moghanlou M, Parvaresh M, Mohammadi S, Khandan M, Aschner M, Mirzaei H, Tamtaji OR. Dadgostar E, et al. Neurotox Res. 2022 Aug;40(4):1096-1102. doi: 10.1007/s12640-022-00526-2. Epub 2022 Jun 6. Neurotox Res. 2022. PMID: 35666433 Review.
COVID-19, from infection to cancer.
Khandan M, Khazeei Tabari MA, Samieefar N, Rezaei N. Khandan M, et al. Acta Biomed. 2022 Oct 26;93(5):e2022224. doi: 10.23750/abm.v93i5.12882. Acta Biomed. 2022. PMID: 36300235 Free PMC article. No abstract available.
107 results